2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W331017
    1-Hexacosanoyl-sn-glycero-3-phosphocholine 1213783-80-2 98%
    1-Hexacosanoyl-sn-glycero-3-phosphocholine (26:0 Lyso PC) is a long-chain fatty acid. 1-Hexacosanoyl-sn-glycero-3-phosphocholine can be used as a biomarker for X-linked adrenoleukodystrophy (ALD) in mice.
    1-Hexacosanoyl-sn-glycero-3-phosphocholine
  • HY-W335927
    MAO-B-IN-19 152897-41-1 98%
    MAO-B-IN-19 is a selective MAO-B inhibitor with an IC50 of 0.67 μM. MAO-B-IN-19 shows neuroprotective and anti-inflammatory properties.
    MAO-B-IN-19
  • HY-W337358
    N-(3-Hydroxyphenyl)-arachidonoyl amide 183718-75-4 98%
    N-(3-Hydroxyphenyl)-arachidonoyl amide (Compound 23) is an anandamide transport inhibitor with an IC50 of 21.3 μM.
    N-(3-Hydroxyphenyl)-arachidonoyl amide
  • HY-W348226
    MMDPPA 858215-05-1 98%
    MMDPPA is an amphetamine and is a precursor in the synthesis of MDA.
    MMDPPA
  • HY-W370556
    (Rac)-LM11A-31 289475-77-0 98%
    (Rac)-LM11A-31 is a racemate of LM11A-31. LM11A-31 is a non-peptide modulator of p75NTR (neurotrophin receptor p75) and is an orally effective proNGF antagonist.
    (Rac)-LM11A-31
  • HY-W392413
    Glutathione monoethyl ester 118421-50-4 98%
    Glutathione monoethyl ester is a glutathione derivative that can protect motor neuron cells NSC-34 from pathology damage caused by mutations in TDP-43, including reducing aggregation formation, nuclear clearance, reactive oxygen species generation, and cell death.
    Glutathione monoethyl ester
  • HY-W396714
    Succinic acid sodium 14047-56-4 98%
    Succinic acid sodium is a potent and orally active anxiolytic agent. Succinic acid sodium shows inhibitory effects on colonic epithelial cell proliferation in vivo. Succinic acid sodium can down-regulate the expression of KCNMB1 (potassium channel subunit β1) and TET1 (ten?eleven translocation 1). Succinic acid sodium can be used for gestational hypertension research.
    Succinic acid sodium
  • HY-W399186
    Methylclonazepam 5527-71-9 98%
    Methylclonazepam is a benzodiazepine with anxiolytic activity. Methylclonazepam inhibits the absorption of 5-hydroxytryptamine by Schistosoma mansoni. Methylclonazepam derivatives have anti-Schistosoma mansoni activity.
    Methylclonazepam
  • HY-W403075
    N-(3-Methoxybenzyl)stearamide 1429659-99-3 98%
    N-(3-Methoxybenzyl)stearamide a natural product from Lepidium meyenii (Maca), inhibits human and mouse soluble epoxide hydrolase (hsEH and msEH) with IC50s of 0.001 and <0.001 μg/nM, respectively.
    N-(3-Methoxybenzyl)stearamide
  • HY-W408969
    4-Methoxy PCE hydrochloride 1933-15-9 98%
    4-Methoxy PCE hydrochloride is an arylcyclohexylamine.
    4-Methoxy PCE hydrochloride
  • HY-W414498
    1-Deoxysphingosine 193222-34-3 98%
    1-Deoxysphingosine is elevated in lymphoblasts of individuals with hereditary sensory neuropathy type 1 (HSAN1) disorder; it features a (4E) double bond in its structure and is produced through the catabolism of 1-deoxyceramide catalyzed by the ceramidase enzyme, classifying it as an unsaturated deoxy-sphingoid base.
    1-Deoxysphingosine
  • HY-W414824
    3β,7β-Dihydroxy-5-cholestenoic acid 1246298-66-7 98%
    3β,7β-Dihydroxy-5-cholestenoic acid is a C27 acid that displays elevated levels in Niemann-Pick type C and Niemann-Pick type B diseases, contributing to toxicity in oculomotor neurons. It is synthesized from 3β-hydroxy-7-oxocholest-5-en-(25R)26-oic acid (3βH,7O-CA) through the enzymatic action of hydroxysteroid 11-β dehydrogenase 1.
    3β,7β-Dihydroxy-5-cholestenoic acid
  • HY-W415121
    Bupivacaine hydrochloride monohydrate 73360-54-0 98%
    Bupivacaine hydrochloride monohydrate is a NMDA receptor inhibitor. Bupivacaine hydrochloride monohydrate can block sodium, L-calcium, and potassium channels. Bupivacaine hydrochloride monohydrate potently blocks SCN5A channels with the IC50 of 69.5 μM. Bupivacaine hydrochloride monohydrate can be used for the research of chronic pain.
    Bupivacaine hydrochloride monohydrate
  • HY-W423643
    Benzedrone 1225617-75-3 98%
    Benzedrone is a synthetic cathinone derivative. Benzedrone can increase the levels of neurotransmitters such as dopamine, serotonin and norepinephrine in the brain, thus producing a stimulant effect. Benzedrone can be used in the research of new psychoactive substances (NPS).
    Benzedrone
  • HY-W424918
    Opromazine hydrochloride 316-07-4 98%
    Opromazine hydrochloride is an antipsychotic medication that exhibits sedative and antiemetic pharmacological effects, making it effective for treating psychiatric disorders such as schizophrenia and psychosis. Opromazine hydrochloride functions by reducing dopaminergic activity through the blockade of dopamine receptors in the brain. Opromazine hydrochloride has been analyzed for its metabolites in various microsomal enzymes, revealing differences in formation rates that underscore the variability of drug-metabolizing enzymes in human liver and placenta microsomes.
    Opromazine hydrochloride
  • HY-W436270
    Bulbocapnine hydrochloride 632-47-3 98%
    Bulbocapnine hydrochloride, an aporphine alkaloid, is a dopamine receptor inhibitor. Bulbocapnine hydrochloride inhibits dopamine synthesis. Bulbocapnine hydrochloride also has neuroleptic-like, anticonvulsant and antinociceptive effects.
    Bulbocapnine hydrochloride
  • HY-W471937
    α1B-AR antagonist 1 874129-03-0 98%
    α1b-AR antagonist 1 (Compound Cpd1) is a selective α1B-AR antagonist. Alpha1b-ar antagonist 1 can be used in the study of cardiovascular and central nervous system diseases.
    α1B-AR antagonist 1
  • HY-W474200
    trans-4-Phenyl-4-piperidinocyclohexanol 78165-07-8 98%
    trans-4-Phenyl-4-piperidinocyclohexanol is structurally categorized as an arylcyclohexylamine and is a metabolite of Phencyclidine.
    trans-4-Phenyl-4-piperidinocyclohexanol
  • HY-W484263
    hnNOS-IN-3 163490-78-6 98%
    hnNOS-IN-3 (compound 39) is a selective nNOS inhibitor, with a Ki of 0.32 μM. The nNOS binding of hnNOS-IN-3 is competitive with L-arginine. The selectivity of hnNOS-IN-3 for nNOS versus iNOS (Ki=37 μM) and eNOS (Ki=9.4 μM) is 115-fold and 29-fold, respectively.
    hnNOS-IN-3
  • HY-W502657
    ZH8667 910387-04-1 98%
    ZH8667 is a trace amine-associated receptor 1 (TAAR1) –Gs agonist. ZH8667 can be used for the research of schizophrenia.
    ZH8667
Cat. No. Product Name / Synonyms Application Reactivity